Targeted radiation for advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new type of radiation therapy that targets kidney cancer cells. It is for people whose cancer has returned or spread after at least two prior treatments, and aims to see if it can shrink tumors and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or spread kidney cancer with a clear cell type.
- You have already received 2 or 3 prior treatments for your cancer, including a PD-1/PD-L1 inhibitor and a VEGF/VEGFR-targeting agent.
- Your cancer has grown or you couldn't tolerate the most recent treatment.
- You have at least one measurable tumor, and a special scan shows your cancer cells have a marker called CAIX.
- You are physically able to perform daily activities (ECOG score 0-1) and your organ function is adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
This study tests a radioactive medicine (called 161Tb-PSMA) that delivers radiation directly to kidney cancer cells that have a specific marker (PSMA). It is for people whose kidney cancer has spread and has not responded to at least two prior treatments. The goal is to see if this new therapy can help shrink the cancer.
This trial tests a combination of precise radiation (SBRT) plus two drugs (anlotinib and bimepolizumab) to see if it helps control advanced kidney cancer. The goal is to shrink tumors and slow the cancer's growth.
Hear when a new ccRCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.